---
run_id: halo-evidence-vs-diagnosis-validation-v11-generic-advice-prompted-06
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
model_condition: generic_advice_prompted
run_number: 6
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 605
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 18fa1d51f6167dbbf1f7ece676734d5cdb459384bca25e1508dd96cd4745e42d
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 31fa87bc7ee0d210ab5e0070b5421b72beac068fc006b3bc3be78b3dd242d5e7
condition_packet_sha256: 31fa87bc7ee0d210ab5e0070b5421b72beac068fc006b3bc3be78b3dd242d5e7
output_file: model-outputs/generic_advice_prompted-06.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 06)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v11-v1`, condition `generic_advice_prompted`, run 6 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 605, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### Reasoning and Tradeoffs

You are currently facing a "false positive" crisis. Your lagging indicators (bookings, renewals) look strong, but your leading indicators (adjuster behavior, health-liability abandonment) are flashing red.

The current growth is likely driven by **sales momentum and pricing incentives**, not **product value**. The "bundle price" created an artificial incentive to renew, and the roadmap pitch created a psychological commitment from buyers that hasn't yet been tested by actual utility. The fact that adjusters revert to manual notes unless monitored suggests SignalPath is currently a "compliance tool" (used because the boss is watching) rather than a "productivity tool" (used because it makes the job easier).

Here is why the other options are insufficient:
*   **Scale Broadly:** This is high-risk. If the product lacks core utility for adjusters, you are scaling a "leaky bucket." You will see a massive spike in churn 12 months from now when the bundle prices expire and the "roadmap promises" are due.
*   **Usage Quality Sprint:** This measures *what* is happening (retention/return rates), but not *why*. You already know the "what": adjusters stop using it after two days. More dashboards won't tell you if the suggestions are wrong or simply unexplainable to regulators.
*   **Commercial Cleanroom:** This tests the *sales pitch*, not the *product*. While it would prove that the bundle pricing is driving growth, it doesn't help you fix the product to ensure those customers actually stay.
*   **Narrow to Health-Liability:** This is a premature pivot. You have evidence of failure in this segment, but you don't yet have a diagnostic of why the product is failing across *all* segments.

The **Claim File Review** is the only option that provides a "ground truth" diagnostic. By looking at whether suggestions were accepted, overridden, or rewritten, you move from *proxy metrics* (usage clicks) to *value metrics* (correctness and utility). This allows you to determine if SignalPath is a "feature" that needs tuning or a "fundamental flaw" in logic.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitatively driven. It does not provide the "hard" financial data that a Board typically wants to see when locking a budget. By choosing this, you are sacrificing the ability to definitively prove—via the Commercial Cleanroom—exactly how much of your recent revenue growth was "fake" (incentive-driven) versus "real" (value-driven). You are betting on **product-market fit** over **revenue attribution**.

### Evidence That Would Change My Mind
I would change this recommendation to the **Commercial Cleanroom** if you discovered that your current cash runway is critically low (e.g., less than 12 months). If the company is in a "survival" mode where you must maximize short-term bookings to avoid a funding crisis, the product's long-term utility is secondary to knowing exactly which pricing levers drive immediate cash. If the goal is survival, you optimize for the sale; if the goal is a sustainable business, you optimize for the Claim File.
